Daniel Welch Email & Phone Number

• Executive with over thirty-five years of experience in world-wide, multi-country and national roles, in biotech and multi-national pharmaceutical companies • Proven track record of exceptional performance leading rapid growth businesses, mature businesses and turnaround situations• Leadership or board director role in bringing breakthrough new medicines to patients with HIV, MS, cardiovascular disease, cancer and rare diseases:• Cardiovascular - Plavix® and Avapro®• Cancer – Eloxatin®, Adcetris®, Padcev®, Tukysa® and Tivdak®• Rare Diseases - Ravicti®, Esbriet®, Ocaliva®, Lokelma®, Mepsevii®, Crysvita®, Dojolvi® and Zolgensma®• Autoimmune and Infectious Disease: Tysabri® and Emtriva® • Led financial transactions of more than $23 billion including $20 billion in five M&A transactions and $3 billion in asset sales, R&D collaborations and financings. • Current or former CEO, Executive Chairman, Non-Executive Chairman, Board Director or Advisor at Avexis, Forma, Hyperion, InCarda Therapeutics, Intercept, InterMune, Levo Therapeutics, Myokardia, Nuvation Bio, Seagen, Triangle Pharma, Ultragenyx, ZS Pharma and others.